Why the study?
Does intravenous C-type natriuretic peptide alter hemodynamics and natriuresis compared to atrial natriuretic peptide in healthy humans?
Does intravenous C-type natriuretic peptide alter hemodynamics and natriuresis compared to atrial natriuretic peptide in healthy humans?
Intravenous CNP exerts significant hypotensive, diuretic, and natriuretic effects in healthy humans, though it is less potent than ANP.
CNP effects in healthy volunteers warrant no practice change; leaves open therapeutic comparisons versus ANP in hypertension or HF.
We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and alpha-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31+/-1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3+/-1.3, -4.1+/-1.0 mmHg) with a significant increase in heart rate (+7.6+/-2.6 bpm), and exerted significant diuretic and natriuretic activities (+130+/-80%, +160+/-100% over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of alpha-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.
No takes yet. Share an insight, caveat, or question.
Igaki et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: